Literature DB >> 24157191

Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents.

Osman Turak1, Uğur Canpolat2, Firat Özcan1, Mehmet Ali Mendi1, Fatih Oksüz1, Ahmet Işleyen1, Ozgül Malçok Gürel3, Serkan Çay1, Dursun Aras1, Sinan Aydoğdu1.   

Abstract

Serum uric acid (SUA) level is known as a significant predictor for cardiovascular diseases, partly through increased inflammatory response and smooth muscle cell proliferation. Inflammation and smooth muscle cells play a crucial role in the pathogenesis of in-stent restenosis (ISR). However, the relation between SUA and ISR has not been studied. The aim of the present study was to investigate the predictive value of preprocedural SUA on the development of ISR in patients who undergo coronary bare-metal stent implantation. Clinical, biochemical, and angiographic data from 708 consecutive patients (mean age 60.3 ± 9.3 years, 71% men) who had undergone bare-metal stent implantation and additional control coronary angiography for stable or unstable angina pectoris were analyzed. Patients were divided into tertiles on the basis of preprocedural SUA levels. Stent restenosis was observed in 54 patients (23%) in the lowest tertile, in 79 (34%) in the middle tertile, and in 109 (46%) in the highest tertile (p <0.001). Using multiple logistic regression analysis, diabetes mellitus, smoking, high-density lipoprotein cholesterol, stent length, C-reactive protein level, and preprocedural SUA level emerged as independent predictors of ISR. On receiver-operating characteristics curve analysis, SUA level >5.5 mg/dl had 75% sensitivity and 71% specificity (area under the curve 0.784, p <0.001) in predicting ISR. In conclusion, higher preprocedural SUA is a powerful and independent predictor of bare-metal stent restenosis in patients with stable and unstable angina pectoris.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157191     DOI: 10.1016/j.amjcard.2013.09.004

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.

Authors:  Mingli Chen; Fangfang Ma; Baohua Su; Caihong Wang; Qun Zheng; Yu Zhang; Meng Li; Shuai Liu; Shuzhi Zhang; Lansuo Yuan
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

2.  New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent.

Authors:  Jian-Long Wang; Zheng Qin; Zhi-Jian Wang; Dong-Mei Shi; Yu-Yang Liu; Ying-Xin Zhao; Li-Xia Yang; Wan-Jun Cheng; Yu-Jie Zhou
Journal:  J Geriatr Cardiol       Date:  2018-02       Impact factor: 3.327

3.  Atherogenic Index of Plasma and the Risk of In-Stent Restenosis in Patients with Acute Coronary Syndrome beyond the Traditional Risk Factors.

Authors:  Yong Zhu; Maolin Chen; Kesen Liu; Ang Gao; Xiangyun Kong; Yan Liu; Hongya Han; Hong Li; Huagang Zhu; Jianwei Zhang; Yingxin Zhao
Journal:  J Atheroscler Thromb       Date:  2021-09-09       Impact factor: 4.394

4.  A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio.

Authors:  Fatih Mehmet Ucar
Journal:  BMC Cardiovasc Disord       Date:  2016-10-03       Impact factor: 2.298

5.  Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.

Authors:  Hyung Joon Joo; Han Saem Jeong; Hyungdon Kook; Seung Hun Lee; Jae Hyoung Park; Soon Jun Hong; Cheol Woong Yu; Do-Sum Lim
Journal:  BMC Cardiovasc Disord       Date:  2018-06-11       Impact factor: 2.298

6.  Association of monocyte to high-density lipoprotein ratio with bare-metal stent restenosis in STEMI patients treated with primary PCI.

Authors:  Ilhan Ilker Avci; Irfan Sahin; Baris Gungor; Mehmet Baran Karatas; Kazim Serhan Ozcan; Yigit Canga; Muhammet Keskin; Mert Ilker Hayiroglu; Fatma Ozpamuk Karadeniz; Aylin Sungur
Journal:  North Clin Istanb       Date:  2018-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.